The Nordic Cochrane Centre, Copenhagen, Denmark.
J R Soc Med. 2011 Sep;104(9):361-9. doi: 10.1258/jrsm.2011.110078.
The information provided to the public by the NHS Breast Screening Programme has been criticized for lack of balance, omission of information on harms and substantially exaggerated estimates of benefit. These shortcomings have been particularly evident in the various invitation leaflets for breast screening and in the Programme's own 2008 Annual Review, which celebrated 20 years of screening. The debate on screening has been heated after new data published in the last two years questioned the benefit and documented substantial harm. We therefore analysed whether the recent debate and new pivotal data about breast screening has had any impact on the contents of the new 2010 leaflet and on the 2010 Annual Review. We conclude that spokespeople for the Programme have stuck to the beliefs about benefit that prevailed 25 years ago. Concerns about over-diagnosis have not been addressed either and official documents still downplay this most important harm of breast cancer screening.
英国国家医疗服务体系（NHS）乳房筛查计划向公众提供的信息因缺乏平衡、遗漏危害信息以及对获益的估计严重夸大而受到批评。这些缺陷在各种乳房筛查邀请传单以及该计划自己的 2008 年度审查中尤为明显，该审查庆祝了 20 年的筛查。在过去两年公布的新数据质疑了筛查的获益并记录了大量危害之后，关于筛查的争论变得激烈起来。因此，我们分析了最近的关于乳房筛查的辩论和新的关键数据是否对新的 2010 年传单的内容以及 2010 年年度审查产生了任何影响。我们的结论是，该计划的发言人坚持了 25 年前流行的关于获益的信念。对过度诊断的担忧也没有得到解决，官方文件仍然淡化了乳腺癌筛查最重要的危害。
